{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.3","upperLimit":"88.9","value":"85.5"},{"groupId":"OG001","lowerLimit":"78.3","upperLimit":"89.4","value":"84.8"}]}],"title":"Survival Probability at Year 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.9","upperLimit":"70.2","value":"65.3"},{"groupId":"OG001","lowerLimit":"49.2","upperLimit":"64.6","value":"57.3"}]}],"title":"Survival Probability at Year 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.0","upperLimit":"54.9","value":"49.6"},{"groupId":"OG001","lowerLimit":"32.9","upperLimit":"48.5","value":"40.8"}]}],"title":"Survival Probability at Year 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"347"},{"groupId":"OG001","value":"174"}],"units":"Participants"}],"description":"One-, Two- or Three-year Survival Probability is defined as the probability of survival 1 year, 2 or 3 years after the date of randomization based on the Kaplan-Meier estimate. Survival time was censored to last date the participant is known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered an initial dose of 125 mg per day orally continuously for 3 weeks followed by 1 week off that can be reduced to 100 mg or 75 mg in case of toxicity; repeated at each subsequent cycle and fulvestrant 500 mg intramuscularly on days 1 and 15 of cycle 1 and then every 28 days. Pre- and perimenopausal women received goserelin at least 4 weeks before study treatment start and continued receiving concurrent ovarian function suppression with goserelin administered subcutaneously every 28 days during the active treatment phase. Maximum treatment duration was 105 cycles.","id":"OG000","title":"Palbociclib + Fulvestrant"},{"description":"Participants were administered placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle and Fulvestrant 500 mg intramuscularly on Days 1 and 15 of cycle 1 and then every 28 days. Pre- and perimenopausal women received goserelin at least 4 weeks before study treatment start and continued receiving concurrent ovarian function suppression with goserelin administered subcutaneously every 28 days during the active treatment phase. Maximum treatment duration was 93 cycles.","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"NUMBER","populationDescription":"The ITT population or full analysis set included all participants who were randomized, with study intervention, regardless of whether participants received the study intervention or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"From randomization until death (assessed up to 36 months)","title":"Survival Probabilities at Year 1, Year 2, and Year 3","type":"SECONDARY","unitOfMeasure":"Survival Probability"}